#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Vascular calcification Pulmonary alveolar haemorrhage Leukoencephalopathy Indolent systemic mastocytosis Nephrotic syndrome Cystic fibrosis gastrointestinal disease Langerhans' cell histiocytosis Immune-mediated myositis Ureteric cancer Langerhans cell sarcoma Metastases to peritoneum Stiff person syndrome Chemical burn Familial amyotrophic lateral sclerosis Hidradenitis More trials…

    Learn about Rare Diseases

    VEXAS syndrome – Life with Disease Biotinidase deficiency – Basic Information Pulmonary fibrosis – Trials in Disease Lymphangioma – Trials in Disease Atypical haemolytic uraemic syndrome – Treatment Brain stem glioma Hyperoxaluria – Life with Disease Hereditary motor and sensory neuropathy – Diagnostics Propionic acidaemia – Treatment Progressive supranuclear palsy More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Treg02 Capecitabine Dexamethasone Isonicotinate Decitabine Tipiracil Hydrochloride Pazopanib Acetylcholine Chloride Ro7247669 Letetresgene Autoleucel Triheptanoin Amikacin Sulfate AZD0516 TETRODOTOXIN Lna043 Mecasermin Rinfabate Lithium Sonelokimab BIIB115 Vidofludimus Calcium Allopurinol More therapies…

    Learn about Your Condition

    Eclampsia Inflammatory bowel disease PIK3CA-activated mutation Bronchiectasis Colorectal cancer stage II Meniscus operation Ehlers-Danlos syndrome Pseudoxanthoma elasticum Transplantation complication Hypertrophic scar Gastrooesophageal cancer Diabetic ketoacidosis Labour induction Glomerulonephritis membranous Otitis media More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Medical Center Akad. Iv. Penchev EOOD

Medical Center Akad. Iv. Penchev EOOD

Ulitsa Zdrave 2, Sofia, 1431, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Obesity
    • Overweight
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Semaglutide
    Bulgaria Croatia Germany Hungary Poland Portugal +1

  • Long-Term Study of Imeroprubart in Adults With Graves’ Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Graves’ disease
    Investigated Drugs:
    • IMEROPRUBART
    Belgium Bulgaria Czechia Germany Greece Hungary +5

  • Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

    Recruiting

    3 1
    Investigated Drugs:
    • HRS 9531
    Bulgaria Czechia Germany Hungary Poland Spain

  • Study of IMVT-1402 Treatment for Adults with Graves’ Disease

    Recruiting

    2 1
    Investigated Drugs:
    • IMEROPRUBART
    Bulgaria Czechia Germany Greece Italy Latvia +3

  • Study of Plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

    Recruiting

    3 1
    Investigated Drugs:
    • Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
    Austria Belgium Bulgaria Croatia Czechia Hungary +6

  • Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

    Recruiting

    3 1 1
    Investigated Drugs:
    • Lanreotide
    • Octreotide
    Austria Belgium Bulgaria Denmark Estonia France +10

  • Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    • Obesity
    • Overweight
    Bulgaria Czechia Denmark France Germany Greece +4

  • Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing’s syndrome

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Cushing’s syndrome
    Investigated Drugs:
    • Dexamethasone
    • Glucose
    • Osilodrostat
    Bulgaria France Germany Italy Poland Romania +1

  • KAI-9531 in Adults With Obesity or Overweight and Diabetes

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Obesity
    Investigated Drugs:
    • HRS 9531
    Bulgaria Czechia Germany Hungary Poland Spain

  • Study on Cefiderocol for Treating Gram-negative Bacterial Infections in Hospitalized Infants Under 3 Months

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Bacterial infection
    Investigated Drugs:
    • Cefiderocol
    Bulgaria Greece Spain
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!